This is a fully human IgG2 monoclonal antibody using the same sequences as the therapeutic antibody evolocumab. It functions as a proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor, in conjunction with LDL cholesterol reducing therapies to aid preventing cardiovascular events and revascularization procedures. Evolocumab binds to PCSK9, inhibiting its binding to LDL receptors on the liver surface, thereby increasing LDL receptors to remove LDL-C from the blood. It is the second PCSK9 inhibitor on the market, first being alirocumab. Evolocumab is able to bind both normal and mutant (D374Y) forms of PCSK9. The exact mechanism of the binding has not been published, however it can be inferred from the precursor molecule mAb1. The mAb1 binds at the catalytic site of PCSK9 through hydrogen bonds and hydrophobic interactions, adjacent to where the LDL receptor binds, resulting in the steric inhibition of binding between PCSK9 and the LDL receptor. By preventing complex formation between these two molecules, internalized LDL receptors are less likely to be degrated by lysosomes and may recycle to the cell surface to remove LDL from circulation.